NCT05650736 - Janus Kinase Inhibition in Granuloma Annulare | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 27, 2023

Primary Completion Date

May 7, 2024

Study Completion Date

July 1, 2025

Conditions

Granuloma Annulare

Interventions

DRUG

Abrocitinib 200 mg

Abrocitinib (Cibinqo) is FDA approved at 200 mg dose once daily for the treatment of atopic dermatitis. It is not currently FDA approved for the treatment of GA.

Trial Locations (1)

06510

Yale University, New Haven